Umer Siddiqui, MD
Pulmonary Disease · Washington, MONPI 1245251321
Payments from drug & device makers
Across 584 payments — averaging $237.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$57K
- Sunovion Pharmaceuticals Inc.$49K
- Mylan Specialty L.p.$28K
- GSK$2K
- Boehringer Ingelheim$404
- Electromed, Inc.$221
- plus $2K from 27 others
What the payments were for
- Consulting fees$3,3422%
- Speaking & faculty fees$116,04084%
- Travel & lodging$9,5397%
- Food & beverage$9,5707%
- Education$1870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 125 | $56,965 |
| Sunovion Pharmaceuticals Inc. | 99 | $48,917 |
| Mylan Specialty L.p. | 84 | $28,176 |
| GSK | 133 | $2,254 |
| Boehringer Ingelheim | 24 | $404 |
| Electromed, Inc. | 23 | $221 |
| Actelion Pharmaceuticals US, Inc. | 5 | $189 |
| Regeneron Healthcare Solutions, Inc. | 12 | $184 |
| Sanofi | 10 | $158 |
| Jazz Pharmaceuticals Inc. | 7 | $144 |
| Philips North America LLC | 6 | $100 |
| United Therapeutics Corporation | 6 | $96 |
| Insmed, Inc. | 6 | $93 |
| Grifols USA, LLC | 5 | $88 |
| Amgen | 5 | $85 |
| ANI Pharmaceuticals, Inc. | 3 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $71 |
| Paratek Pharmaceuticals, Inc. | 4 | $71 |
| Harmony Biosciences LLC | 3 | $57 |
| Fisher & Paykel Healthcare Inc | 3 | $46 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $44 |
| Resmed Corp | 2 | $34 |
| Merck | 2 | $28 |
| Baxter Healthcare | 2 | $25 |
| Lilly USA, LLC | 1 | $24 |
| Pulmonx Corporation | 1 | $21 |
| Viatris Specialty LLC | 1 | $19 |
| Tactile Systems Technology Inc | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Inspire Medical Systems, Inc. | 1 | $14 |
| Verona Pharma, Inc. | 1 | $14 |
| Ambu Inc. | 1 | $12 |
| Itamar Medical Inc | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LONHALA MAGNAIR$47,567
- BREZTRI$42,462
- Yupelri$27,427
- BREZTRI AEROSPHERE$12,896
- AIRSUPRA$636
- FASENRA$636
- TEZSPIRE$357
- NUCALA$242
- FARXIGA$224
- TRELEGY ELLIPTA$125
- UPTRAVI$122
- OPSUMIT$122
- AREXVY$121
- ANORO$108
How this compares
$138,678 in reported general payments places this provider in the 85th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 1,392 | $1,150,690 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 553 | $430,920 |
| ZemairaAlpha-1-Proteinase Inhibitor | 19 | $171,608 |
| Spiriva RespimatTiotropium Bromide | 167 | $109,024 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 197 | $95,127 |
| Breo ElliptaFluticasone/Vilanterol | 186 | $88,004 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 133 | $80,467 |
| Incruse ElliptaUmeclidinium Bromide | 126 | $52,689 |
| Dupixent PenDupilumab | 12 | $49,711 |
| SymbicortBudesonide/Formoterol Fumarate | 157 | $45,659 |
| EliquisApixaban | 56 | $38,759 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 59 | $29,234 |
| Spiriva HandihalerTiotropium Bromide | 48 | $27,723 |
| Roflumilast | 351 | $27,673 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 1,089 | $26,660 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arexvy | $2,254 | $1,407,7291,982 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $56,965 | $476,579710 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $404 | $218,725359 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 295 pulmonary disease providers in Missouri.
Other pulmonary disease in Washington
- Adeel KhanWashington$316K
- Steven HullLees Summit$10.1M
- Thomas SilerSaint Charles$5.5M
- Neil EttingerChesterfield$3.5M
- Humam FarahHannibal$2.7M
- Murali ChakinalaSaint Louis$2.4M
- Joseph OjileSaint Louis$2.1M
- Jeffrey HarrisSaint Louis$1.1M
- Kaharu SuminoSaint Louis$1.1M
- Tonya RussellSaint Louis$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.